A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
Status:
Unknown status
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the first phase of the study is to determine whether, and at what dose,
depsipeptide, bortezomib and dexamethasone can be safely administered to patients with
Multiple Myeloma. The second phase of the study will establish whether depsipeptide,
bortezomib and dexamethasone is effective in the treatment of patients with multiple myeloma.
The study will also examine the role of maintenance therapy with depsipeptide.